July 10, 2020 by Chain Drug Review
mylan, Robert Coury, Upjohn, Viatris
Leading Headlines, Pharmacy
HERTFORDSHIRE, England— Mylan and Upjohn, a division of Pfizer, unveiled on Thursday the logo and branding for Viatris, the new company that will be formed by combining Mylan and Upjohn. Viatris will benefit from Mylan and Upjohn’s trusted global offerings and legacy of meeting patient needs around the world. The new logo and branding is
November 14, 2019 by Chain Drug Review
mylan, Pfzer, Robert Coury, Viatris
Pharmacy, Supplier News
NEW YORK — Mylan and Pfizer announced earlier this week that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding
July 29, 2019 by Chain Drug Review
Heather Bresch, Ken Parks, mylan, Pfizer, Rajiv Malik, Robert Coury, Upjohn
Business, Featured Articles, Leading Headlines, Pharmacy, Supplier News
NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of
February 11, 2016 by Chain Drug Review
Heather Bresch, Jörg-Thomas Dierks, Meda, mylan, Perrigo, Peter von Ehrenheim, Robert Coury
Leading Headlines, Pharmacy, Supplier News
HERTFORDSHIRE, England — Mylan N.V. plans to acquire Sweden-based pharmaceuticals manufacturer Meda AB in a deal valued at $9.9 billion, including debt. Mylan said late Wednesday that the offer to Meda includes cash and Mylan shares, with the equity portion valued at $7.2 billion. Executives from both companies noted that a Mylan-Meda combination would create
November 13, 2015 by Chain Drug Review
Joseph Papa, mylan, Perrigo, Robert Coury
Leading Headlines, Pharmacy, Supplier News
NEW YORK — Shareholders of Perrigo Co. plc have rejected a hostile bid by Mylan N.V. to acquire the company in a deal valued at about $27 billion. Perrigo said Friday that shareholders holding more than 60% of its outstanding shares declined to tender into Mylan’s offer by the 8 a.m. ET deadline. The offer
November 4, 2015 by Chain Drug Review
mylan, Perrigo, Robert Coury
Leading Headlines, Pharmacy, Supplier News
NEW YORK — Mylan N.V. has received clearance from the Federal Trade Commission for its proposal to acquire Perrigo Co. plc after agreeing to divest certain generic drug products. The regulatory approval leaves Mylan’s hostile bid in the hands of Perrigo shareholders, who have until Nov. 13 to accept the tender offer. To proceed with
September 14, 2015 by Chain Drug Review and Chain Drug Review
Heather Bresch, Joseph Papa, mylan, Perrigo, Robert Coury
Leading Headlines, Pharmacy, Supplier News
HERTFORDSHIRE, England — As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share. That would translate to a
September 8, 2015 by Chain Drug Review
Joseph Papa, mylan, Perrigo, Robert Coury
Pharmacy, Supplier News
HERTFORDSHIRE, England — Next week, Mylan N.V. plans to make a formal offer directly to the shareholders of Perrigo plc to buy the company. Mylan said Tuesday that it aims to make the bid on Monday, Sept. 14. Under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each
April 29, 2015 by Chain Drug Review and Chain Drug Review
Heather Bresch, Joe Papa, mylan, Perrigo, Robert Coury, Teva Pharmaceutical Industries
Supplier News
NEW YORK — Mylan N.V. has upped its offer to acquire Perrigo Co. plc but received the same response: no. On Wednesday, Mylan announced an increased bid in which Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share, a deal valued at more than $35 billion. But
April 27, 2015 by Chain Drug Review and Chain Drug Review
Erez Vigodman, mylan, Perrigo, Robert Coury, Teva Pharmaceutical Industries
Supplier News
POTTERS BAR, England — Mylan N.V. has rejected an unsolicited bid to be acquired by Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at more than $40 billion. Mylan said Monday that its board of directors unanimously voted against Teva’s offer, which was announced on April 21. Mylan stated that after a comprehensive review
April 21, 2015 by Chain Drug Review
Erez Vigodman, mylan, Perrigo, Robert Coury, Teva Pharmaceutical Industries
Featured Articles, Leading Headlines, Pharmacy, Supplier News
JERUSALEM — Teva Pharmaceutical Industries Ltd. has made a bid to acquire Mylan N.V. in a cash-and-stock deal valued at about $40 billion. In announcing its offer Tuesday, Teva said its proposal is a more attractive option for shareholders of Mylan, which nearly two weeks ago made an unsolicited bid to buy Perrigo Co. plc
April 8, 2015 by Chain Drug Review and Chain Drug Review
Joseph Papa, mylan, Perrigo, Robert Coury
Leading Headlines, Pharmacy, Supplier News
POTTERS BAR, England — Mylan N.V. has made an unsolicited bid to acquire Dublin, Ireland-based Perrigo Co. plc in a cash-and-stock deal valued at about $29 billion. Mylan said Wednesday that under the proposal — delivered to Perrigo chairman, president and chief executive officer Joseph Papa — Perrigo shareholders would receive $205 in cash and